The University of Texas Health Science Center at San Antonio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, The University of Texas Health Science Center at San Antonio sits in the top decile of US sponsors by registered trial count (#94 of 15,742 sponsors by registered trial count).
The University of Texas Health Science Center at San Antonio: 378 sponsored US clinical trials, 77 recruiting.
The University of Texas Health Science Center at San Antonio sponsors 378 registered US clinical trials on ClinicalTrials.gov, 77 of them currently recruiting, and 264 completed. 41 of these trials are in Phase 3-4 (later-stage) and 124 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes, with 13 trials.
Top-decile sponsor footprint
The University of Texas Health Science Center at San Antonio ranks in the top decile of sponsors by registered trial count (#94 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
264 of 284 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
378 total, page 8 of 8
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
NCT00055822
Cytokine Regulation of Periradicular Pain in Humans
NCT00223470
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
NCT00227110
Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer
NCT00049062
A Pilot Study of Psychodynamic Psychotherapy for Bipolar Disorder
NCT00330005
Erlotinib in Treating Patients With Advanced Kidney Cancer
NCT00045487
Treating Thought Problems in Patients With Schizophrenia
NCT00051740
ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
NCT00030524
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors
NCT00223366
A Brief Intervention to Improve Medication Knowledge and Adherence Among Family Medicine Patients in South Texas
NCT00846300
Neuropeptide Y (NPY) Regulation of Nociceptors
NCT00596193
Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
NCT00127387
Growth Hormone and Chromosome 18q- and Abnormal Growth
NCT00134420
CCI-779 in Treating Patients With Advanced Solid Tumors
NCT00003712
Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia
NCT00455663
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00004870
Quantitative Gait Analysis for Clinical Decision Making
NCT00223353
Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00003721
Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer
NCT00003760
Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00003709
This Study Compared an in Home Asthma Management Program Provided by Nurses or Respiratory Therapist
NCT00639847
Combination Chemotherapy in Treating Patients With Advanced Cancer
NCT00003707
Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors
NCT00003710
Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00003708
LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function
NCT00003706
Clinical Performance of 3-Unit FPDs
NCT00223431
Bizelesin in Treating Patients With Advanced Cancer
NCT00003021
Project Sexual Awareness for Everyone (SAFE)
NCT00643019
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 79 |
| Phase 2 | 45 |
| Phase 3 | 8 |
| Phase 4 | 33 |
Therapeutic Areas
What is open in the The University of Texas Health Science Center at San Antonio pipeline
77 recruiting of 378 indexed (20% open); 264 completed (70%).
Phase mix: 41 late (III/IV) vs 124 early (I/II) (early-phase heavy).
Top condition: Type 2 Diabetes (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
The University of Texas Health Science Center at San Antonio: open-pipeline peers nationwide
Peers matched on 378 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
The University of Texas Health Science Center at San Antonio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 378 trials (± recruiting share)
- Northwell Health · 370 trials · 22% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
Sponsors near 20% open enrollment (± trial volume)
- M.D. Anderson Cancer Center · 20% recruiting · 2,692 trials
- University of Georgia · 20% recruiting · 59 trials
- University of Houston · 20% recruiting · 64 trials
- Florida International University · 20% recruiting · 89 trials
Related
What to do with this The University of Texas Health Science Center at San Antonio page
378 registered trials is a research-attention snapshot, not an endorsement of The University of Texas Health Science Center at San Antonio or any single study.
- 77 of The University of Texas Health Science Center at San Antonio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Type 2 Diabetes is the condition The University of Texas Health Science Center at San Antonio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 2 Diabetes trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. The University of Texas Health Science Center at San Antonio pipeline card: 378 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.